Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Input metadata referenced "Vericel Corp," but the filing text identifies the registrant as Aastrom Biosciences, Inc.)
Reporting Period: Quarter ended September 30, 2010 (Fiscal Q1 2011).
Business Stage: Clinical development stage company focused on autologous cell therapies for regenerative medicine, specifically targeting Critical Limb Ischemia (CLI) and Dilated Cardiomyopathy (DCM).
Operations: The company operates in one segment involving research and product development. It has not yet achieved commercial profitability and relies on equity financing and grants.
Key Financial Metrics
| Metric (in thousands) | Q3 2010 | Q3 2009 | Balance Sheet (Sep 30, 2010) |
|---|---|---|---|
| Total Revenues | $0 | $73 | N/A |
| Net Loss | $(5,833) | $(3,801) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.21) | $(0.18) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $14,466 |
| Total Assets | N/A | N/A | $15,970 |
| Total Liabilities | N/A | N/A | $3,527 |
| Shareholders' Equity | N/A | N/A | $12,443 |
| Accumulated Deficit | N/A | N/A | $(219,385) |
Expense Breakdown (Q3 2010):
- Research and Development (R&D): $4,167,000
- Selling, General and Administrative (SG&A): $1,686,000
- Stock-based compensation included in R&D: $255,000
- Stock-based compensation included in SG&A: $230,000
Material Changes vs. Prior Period
- Revenue: Revenue dropped to $0 from $73,000 in the prior year quarter. The 2009 revenue consisted of minor sales of cell products and manufacturing supplies for investigator-sponsored trials.
- Net Loss: Net loss increased by approximately 53% to $5.83 million from $3.80 million. This was driven by increased operating expenses.
- R&D Expenses: Increased by $1.26 million (43%) to $4.17 million, primarily due to preparations for the Phase 3 CLI development program and increased headcount.
- SG&A Expenses: Increased by $740,000 (79%) to $1.69 million. This increase was due to new senior management hires and a reversal of stock-based compensation expense in the prior year (related to a former executive's forfeiture) which is not present in the current period.
- Liquidity: Cash and cash equivalents decreased by $4.65 million from the previous quarter end (June 30, 2010) to $14.47 million, reflecting cash burn from operations and capital expenditures.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Liquidity Runway: Management believes current cash ($14.47 million) is sufficient to fund operations through at least June 30, 2011. The company may delay discretionary expenditures or slow non-critical clinical trials if necessary to extend this runway.
- Capital Needs: The company will need to raise additional funds to complete product development, specifically the Phase 3 CLI trial, and to commercialize products. There is no assurance that funding will be available on favorable terms.
- Clinical Progress:
- CLI (Critical Limb Ischemia): Phase 2b RESTORE-CLI interim analysis showed statistically significant improvement in amputation-free survival (p=0.038). FDA granted Fast Track designation in October 2010. Phase 3 program planning is underway.
- DCM (Dilated Cardiomyopathy): Two Phase 2 trials are ongoing (surgical and catheter-based). Enrollment for the surgical trial (IMPACT-DCM) is complete; the catheter trial is progressing.
Risks and Contingencies:
- Profitability: The company has never been profitable and does not anticipate net income until significant product sales commence, which is not expected for several years.
- Regulatory Risk: Success depends on obtaining FDA approval (Biologics License Application). Delays or failures in clinical trials or regulatory approval could materially adversely affect the company.
- Financing Risk: Continued operations depend on the ability to raise additional capital through equity or debt offerings, which may be dilutive or unavailable.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $4.55 million quarterly cash burn against the $14.47 million cash balance to confirm the June 2011 runway estimate.
- Phase 3 CLI Trial Design: Confirm the status of the Special Protocol Assessment (SPA) submitted to the FDA and the timeline for initiating the Phase 3 trial.
- Capital Raise Plans: Monitor for announcements regarding new equity offerings or strategic partnerships required to fund the Phase 3 trial and commercialization.
- Stock-Based Compensation: Review the $2.62 million of unrecognized compensation cost related to non-vested options, which will impact future earnings.
- Clinical Data: Await the six-month data presentation for the RESTORE-CLI trial and interim results for the IMPACT-DCM trial expected in fiscal year 2011.